XML 87 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenue    
Collaboration and license revenue $ 2,816 $ 21,049
Operating expenses:    
Research and development 107,350 88,153
General and administrative 30,287 26,354
Loss from operations (134,821) (93,458)
Other (expense) income:    
Interest and other income, net 12,065 7,999
Interest expense 3,653 3,759
Loss on extinguishment of debt (1,090)  
Net loss (127,499) (89,218)
Reportable Segment    
Revenue    
Collaboration and license revenue 2,816 21,049
Operating expenses:    
Loss from operations (134,821) (93,458)
Other (expense) income:    
Interest and other income, net 12,065 7,999
Interest expense (3,653) (3,759)
Loss on extinguishment of debt (1,090)  
Net loss (127,499) (89,218)
Reportable Segment | Personnel Expenses    
Operating expenses:    
Research and development 31,742 24,165
General and administrative 10,900 9,065
Reportable Segment | Laboratory Supplies, Research Materials and Studies    
Operating expenses:    
Research and development 31,468 30,101
Reportable Segment | Clinical Studies    
Operating expenses:    
Research and development 19,245 10,214
Reportable Segment | Legal and Professional Fees    
Operating expenses:    
General and administrative 7,380 7,119
Reportable Segment | Facility-Related and Other    
Operating expenses:    
Research and development 16,669 16,298
General and administrative 6,576 6,976
Reportable Segment | Stock-Based Compensation    
Operating expenses:    
Research and development 4,846 2,876
General and administrative 4,703 2,332
Reportable Segment | Depreciation Expense    
Operating expenses:    
Research and development 3,380 4,499
General and administrative $ 728 $ 862